Le Lézard
Classified in: Health
Subject: PLW

GastroGeniX Collaborates with the University of Saskatchewan on Patent License to Advance Capsule Endoscopy


SAN RAFAEL, Calif., Jan. 17, 2018 /PRNewswire/ -- ­GastroGeniX, Inc., (http://www.gastrogenix.co/) San Rafael, CA. U.S.A, and the University of Saskatchewan have reached an agreement to License United States Patent 9,088,716B2, and all associated intellectual properties, to GastroGenix Inc.

White Light Endoscopy has long been the standard of care for diagnosing Gastrointestinal Metaplasia as a cancer precursor. Recent studies and peer reviewed, blinded clinical trials have begun to clearly establish the superiority of narrow band imaging to improve the detection of Gastrointestinal Metaplasia and Cancer. (https://www.ncbi.nlm.nih.gov/pubmed/28366441).

The Patent(s) establish new methods for image processing in Wireless Capsule Endoscopy. The image processing techniques exploit characteristic features of endoscopic images to enable low complexity compression and a color publication classification space conversion, coupled with lossless predictive coding, variable length coding, sub-sampling and clipping. The image processing can be used with both white-band and narrow-band imaging. Thereby, potentially improving the efficacy of white light endoscopy in combination with NIB.

"The data is clear, High Definition White Light Endoscopy is insufficient for detection of Gastrointestinal Metaplasia in patients at increased risk for Gastric Cancer. Narrow Band Imaging targeted biopsies plus mapping biopsies should be used," stated Larry Gerrans, Founder and President of GastroGeniX. "This patent, our relationship with the scientists at the University of Saskatchewan and our focus on distinctly new and innovative, multi-modal imaging and treatment systems are purposed to deliver the future of intervention and the reduction of cancer in the GI system for patients globally."   

Wireless Capsule Endoscopy (WCE) was first developed by Given Imaging in the late 1990s, coming to market in the US in August of 2001. This technology radically changed the way that diseases of the small intestine were viewed by the medical community, giving, for the first time, video streams of the gut in it's natural physioligic state, and providing direct access to the 20+ feet of the intestine not accessible without surgery or specialized instrumentation. Patients could ingest the video capsule in an office setting, then be on their way to have a normal day. The image data was transmitted to a recording device on their belt, which was retrieved and downloaded at the end of the day, for a physician to read on a computer. Once insurance payers recognized the value and began reimbursing, the technology took off and became a standardized tool for the GI community.

Most technologies evolve over time, and WCE has certainly done that. Increasingly sophisticated software automations have shortened read times and rendered new image structures, for example.   Other capsule-based systems interpret physiologic metrics, such as transit/emptying time and gut pH.

"There are still new frontiers to cross, however, and this patent and technology coupled with our existing technology development initiatives opens the door for our next generation of multi-modality capsule platforms to emerge, giving physicians and patients a broader array of diagnostic capabilities," related Mike Humason, VP Clinical Affairs and Education, who was a distinguished member of the original Given Imaging team in the early 2000s. "GastroGeniX is excited to contribute to the next generation of capsule-based diagnostic tools for the gastroenterology community."

Media Contact:

Steve Goldsmith
(415) 729 9391 x1023
[email protected]

SOURCE GastroGeniX


These press releases may also interest you

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
Closed System Transfer Devices Market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....



News published on and distributed by: